Abuse potential of dronabinol (marinol®)

Journal of Psychoactive Drugs

Volumn 30, Issue 2, 1998, Pages 187-196

  Calhoun, Sarah R ^a   Galloway, Gantt P ^a   Smith, David E ^a  

^a Haight Ashbury Free Clinics   (United States)

Author keywords

Abuse potential; Dronabinol; Oncology; Wasting syndrome

Indexed keywords

DRONABINOL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER CHEMOTHERAPY; CONTROL SYSTEM; DRUG ABUSE; DRUG EFFECT; HUMAN; MONITORING; ORAL DRUG ADMINISTRATION; REINFORCEMENT; REVIEW; SAFETY; WASTING SYNDROME;

ANTIEMETICS; APPETITE STIMULANTS; DATA COLLECTION; HUMANS; SUBSTANCE-RELATED DISORDERS; TETRAHYDROCANNABINOL;

EID: 0031876250     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.1998.10399689     Document Type: Article

References (28)

1. Agurell, S.; Gillespie, H.; Halldin, M.; et al. 1984. A review of recent studies on the pharmacokinetics and metabolism of delta-1 -tetrahydrocannabinol, cannabidiol and cannabinol in man. In: D.J. Harvey (Ed.) Marijuana '84: Proceedings of the Oxford Symposium on Cannabis. Oxford: IRL Press.
2. Beal, J.A. 1994. Appetite effect of dronabinol. Journal of Clinical Oncology 12(7): 1524-25.
3. Beal, J.E.; Olson, R.; Laubenstein, L.; Morales, J.O.; Bellman, P.; Yangco, B.; Lefkowitz, L.; Plasse, T.F.; Shepard, K.V. 1995. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Journal of Pain and Symptom Management 10 (2): 89-97.
4. Chait, L.D. & Zacny J.P 1992. Reinforcing and subjective effects of oral delta-9-THC and smoked marijuana in humans. Psychopharmacology 107:255-62.
5. Doblin, R.E. & Kleiman, M.A. 1991. Marijuana as antiemetic medicine: A survey of oncologists' experiences and attitudes. Journal of Clinical Oncology 9 (7): 1314-19.
6. Gorman, P. 1996. Ralph Seeley: Fighting for life. High Times February.
7. Gorter, R. 1991. Management of anorexia-cachexia associated with cancer and HIV infection. Oncology 5 (9 Suppl): 13-17.
8. Gorter, R.; Seefried, M. & Volberding, P. 1992. Dronabinol effects on weight in patients with HIV infection. AIDS 6 (1): 127.
9. Hellinger, F.J. 1993. The lifetime cost of treating a person with HIV. Journal of the American Medical Association 270 (4): 474-78.
10. Kotler, D.P. 1994. Wasting syndrome: Nutritional support in HIV infection. AIDS Research and Human Retroviruses 10 (8): 931-34.
11. Lane, M.; Smith, F.E.; Sullivan, R.A. & Plasse, T.F. 1990. Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy. American Journal of Clinical Oncology 13 (6): 480-84.
12. Lane, M.; Vogel, C.L.; Ferguson, J.; Krasnow, S.; Saiers, J.L.; Jamm, J.; Salva, K.; Wiemik, PH.; Holroyde, C.P.; Hammill, S.; Shepard, K. & Plasse, T. 1991. Dronabinol and prochlorperazine in combination for treatment of cancer and chemotherapy-induced nausea and vomiting. Journal of Pain and Symptom Management 6 (6): 352-59.
13. McMahon, J. 1998. Press release.
14. Manzo, M. 1988. Dronabinol and nabilone ease cancer chemotherapy. Nursing 18 (8): 81.
15. Mattes, R.D.; Shaw, L.M.; Edling-Owens, J.; Engelman, K. & Elsohly, M.A. 1993. Bypassing the first-pass effect for the therapeutic use ofcannabinoids. Pharmacology, Biochemistry and Behavior 44 (3): 745-47.
16. Medical Economics Company. 1996. Physicians' Desk Reference, 50th Ed. Montvale, New Jersey: Medical Economics Company.
17. Mendelson, J.H. & Mello, N.K. 1984. Reinforcing properties oforal delta-9-tetrahydrocannabinol, smoked marijuana and nabilone: Influence of previous marijuana use. Psychopharmacology 83:351-56.
18. Nelson, K.A.; Walsh, D. & Sheehan, F.A. 1994. The cancer anorexia-cachexia syndrome. Journal of Clinical Oncology 12(1): 213-25.
19. Nguyen, P.B. 1993. Dronabinol in tremor. Annals of Pharmacotherapy 27 (II): 1357-58.
20. O'Brien, C.P. 1996. Drug addiction and abuse. In: J.G. Hardin; L.E. Limbird; P.B. Malinoff; R.W. Ruddon & A.G. Gilman (Eds.) Goodman & Gilman's The Pharmacological Basis of Therapeutics New York: McGraw Hill.
21. Plasse, T.F. 1991. Clinical use of dronabinol. Journal of Clinical Oncology 9 (II): 2079-80.
22. Plasse, T.F.; Gorter, R.W.; Krasnow, S.H.; Lane, M.; Shepard, K.V. & Wadleigh, R.G. 1991. Recent clinical experience with dronabinol. Pharmacology, Biochemistry & Behavior 40 (3): 695-700.
23. Schwartz, R.H. 1992. Medical use of marijuana. Annals of Inteirnal Medicine 117 (3): 268-69.
24. Schwartz, R.H. & Beveridge R.A. 1994. Marijuana as an antiemetic drug: How useful is it today? Opinions from clinical oncologists. Journal of Addictive Diseases 13 (I): 53-65.
25. Shepard, K.V. 1993. The cost of Marinol (dronabinol). Journal of the American Medical Association 270 (23): 2810.
26. Smith, D.E. & Seymour, R.B. 1997. Cannabis and cannabis withdrawal. Journal of Substance Abuse Treatment 2 (1): 49-53.
27. Struwe, M.; Kaempfer, S.H.; Geiger, C.J.; Pavia, A.T.; Plasse, T.F.; Shepard, K.V.; Ries, K. & Evans, T.G. 1993. Effect of dronabinol on nutritional status in HIV infection. Annals of Pharmacotherapy. 27 (7-8): 827-31.
28. Tchekmedyian, N.S. 1993. Clinical approaches to nutritional support in cancer. Current Opinion in Oncology 5 (4): 633-38.